Autor segons l'article: Parra, S; Heras, M; Herrero, P; Amigó, N; Garcés, E; Girona, J; Correig, X; Canela, N; Castro, A
Departament: Enginyeria Electrònica, Elèctrica i Automàtica Medicina i Cirurgia
Autor/s de la URV: Castro Salomó, Antoni / Correig Blanchar, Francesc Xavier / Girona Tell, Josefa / HERAS IBAÑEZ, MERCEDES / HERRERO GIL, POL / Parra Pérez, Sandra
Paraules clau: Antibodies Antiinflammatory properties Antimalarial Apolipoprotein-a-i Atherosclerosis Biomarker Gelsolin High-density lipoprotein (hdl) High-density-lipoprotein Innate Mechanisms Protein Proteome Rheumatoid-arthritis Systemic lupus erythematosus Systemic-lupus-erythematosus
Resum: To identify potential biomarkers of disease activity analysing the proteome of high-density lipoprotein (HDL) particles from SLE patients in clinical remission and when they develop a flare compared with a healthy control group.Quantitative proteomic analyses of purified HDL were performed using Tandem Mass Tag isobaric tag-labelling and nanoLC-Orbitrap (nLC-MS/MS) from nine SLE patients in clinical remission when they developed a flare and from nine healthy controls (9-9-9). We verified the identified proteins by Western blot and ELISA in a cohort of 104 SLE women patients, 46 healthy women and 14 SLE patients when a flare developed.We found 17 proteins with a significant fold-change (>1.1) compared with the control group. In lupus patients experiencing a flare compared with those in remission, we identified four proteins with a significant fold-change (C4, Indian Hedgehog protein, S100A8 and gelsolin). Plasma gelsolin (pGSN) levels were decreased in the 104 SLE patients (176.02(74.9) mcg/l) compared with the control group (217.13(86.7) mcg/l); P=0.005 and when they developed a clinical flare (104.84(41.7) mcg/l); P=0.002). pGSN levels were associated with HDL cholesterol levels (r = 0.316, P<0.001). Antimalarial treated patients showed significant higher levels of pGSN (214.56(88.94) mcg/l regarding 170.35(66.36) mcg/l); P = 0.017.Decreased pGSN are associated with clinical disease activity in SLE patients. Antimalarial treatment and HDL cholesterol are associated with higher levels of pGSN.© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Àrees temàtiques: Biotecnología Ciência de alimentos Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Ensino Farmacia General medicine Interdisciplinar Medicina i Medicina ii Medicina iii Odontología Pharmacology (medical) Rheumatology Saúde coletiva
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: sandra.parra@urv.cat josefa.girona@urv.cat antoni.castro@urv.cat xavier.correig@urv.cat josefa.girona@urv.cat
ISSN: 0080-2727
Identificador de l'autor: 0000-0001-9363-6574 0000-0002-6267-8779 0000-0001-5441-6333 0000-0002-6902-3054 0000-0002-6267-8779
Data d'alta del registre: 2024-01-27
Versió de l'article dipositat: info:eu-repo/semantics/submittedVersion
Referència a l'article segons font original: Rheumatology. 59 (3): 650-661
Referència de l'ítem segons les normes APA: Parra, S; Heras, M; Herrero, P; Amigó, N; Garcés, E; Girona, J; Correig, X; Canela, N; Castro, A (2020). Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology, 59(3), 650-661. DOI: 10.1093/rheumatology/kez293
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2020
Tipus de publicació: Journal Publications
Repositori URV